152 related articles for article (PubMed ID: 29858790)
61. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
62.
Li X; Yin G; Ji W; Liu J; Zhang Y; Wang J; Zhu X; Zhu L; Dai D; Ma W; Xu W
Onco Targets Ther; 2020; 13():11659-11668. PubMed ID: 33223839
[TBL] [Abstract][Full Text] [Related]
63. Targeting CAIX with [
Yang X; Zhu H; Yang X; Li N; Huang H; Liu T; Guo X; Xu X; Xia L; Deng C; Tian X; Yang Z
Mol Pharm; 2019 Apr; 16(4):1532-1540. PubMed ID: 30803240
[TBL] [Abstract][Full Text] [Related]
64. Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor.
Johnson M; Karanikolas BD; Priceman SJ; Powell R; Black ME; Wu HM; Czernin J; Huang SC; Wu L
J Nucl Med; 2009 May; 50(5):757-64. PubMed ID: 19372484
[TBL] [Abstract][Full Text] [Related]
65. Tumor lysing genetically engineered T cells loaded with multi-modal imaging agents.
Bhatnagar P; Alauddin M; Bankson JA; Kirui D; Seifi P; Huls H; Lee DA; Babakhani A; Ferrari M; Li KC; Cooper LJ
Sci Rep; 2014 Mar; 4():4502. PubMed ID: 24675806
[TBL] [Abstract][Full Text] [Related]
66. Development of a universal anti-polyethylene glycol reporter gene for noninvasive imaging of PEGylated probes.
Chuang KH; Wang HE; Cheng TC; Tzou SC; Tseng WL; Hung WC; Tai MH; Chang TK; Roffler SR; Cheng TL
J Nucl Med; 2010 Jun; 51(6):933-41. PubMed ID: 20484433
[TBL] [Abstract][Full Text] [Related]
67. Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells.
Ashmore-Harris C; Iafrate M; Saleem A; Fruhwirth GO
Mol Ther; 2020 Jun; 28(6):1392-1416. PubMed ID: 32243834
[TBL] [Abstract][Full Text] [Related]
68. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
69. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
Persson M; Liu H; Madsen J; Cheng Z; Kjaer A
Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763
[TBL] [Abstract][Full Text] [Related]
70. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
Milone MC; Fish JD; Carpenito C; Carroll RG; Binder GK; Teachey D; Samanta M; Lakhal M; Gloss B; Danet-Desnoyers G; Campana D; Riley JL; Grupp SA; June CH
Mol Ther; 2009 Aug; 17(8):1453-64. PubMed ID: 19384291
[TBL] [Abstract][Full Text] [Related]
71. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging.
Hung SC; Deng WP; Yang WK; Liu RS; Lee CC; Su TC; Lin RJ; Yang DM; Chang CW; Chen WH; Wei HJ; Gelovani JG
Clin Cancer Res; 2005 Nov; 11(21):7749-56. PubMed ID: 16278396
[TBL] [Abstract][Full Text] [Related]
72. Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging.
Lee SH; Soh H; Chung JH; Cho EH; Lee SJ; Ju JM; Sheen JH; Kim H; Oh SJ; Lee SJ; Chung J; Choi K; Kim SY; Ryu JS
PLoS One; 2020; 15(1):e0223814. PubMed ID: 31910217
[TBL] [Abstract][Full Text] [Related]
73. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
74. Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo.
Tavaré R; McCracken MN; Zettlitz KA; Knowles SM; Salazar FB; Olafsen T; Witte ON; Wu AM
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1108-13. PubMed ID: 24390540
[TBL] [Abstract][Full Text] [Related]
75. Novel multifunctional
Kwon YD; Lee JY; La MT; Lee SJ; Lee SH; Park JH; Kim HK
Eur J Med Chem; 2020 Mar; 189():112099. PubMed ID: 32014792
[TBL] [Abstract][Full Text] [Related]
76. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
[TBL] [Abstract][Full Text] [Related]
77. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
78. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
[TBL] [Abstract][Full Text] [Related]
79. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer
Stutvoet TS; van der Veen EL; Kol A; Antunes IF; de Vries EFJ; Hospers GAP; de Vries EGE; de Jong S; Lub-de Hooge MN
J Nucl Med; 2020 Dec; 61(12):1839-1844. PubMed ID: 32358092
[No Abstract] [Full Text] [Related]
80. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
Cheal SM; Punzalan B; Doran MG; Evans MJ; Osborne JR; Lewis JS; Zanzonico P; Larson SM
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
